tiprankstipranks
Advertisement
Advertisement

HK:2496 Stock Latest News

Wuhan YZY Biopharma Narrows Interim Loss but Net Liabilities Deepen
Company AnnouncementsWuhan YZY Biopharma Narrows Interim Loss but Net Liabilities Deepen
5h ago
2496
Wuhan YZY Biopharma Sets Board Meeting to Approve Interim 2026 Results
PremiumCompany Announcements
Wuhan YZY Biopharma Sets Board Meeting to Approve Interim 2026 Results
10d ago
2496
Wuhan YZY Biopharma AGM Approves 2025 Results, Profit Plan and Auditor Reappointment
PremiumCompany Announcements
Wuhan YZY Biopharma AGM Approves 2025 Results, Profit Plan and Auditor Reappointment
2M ago
2496
Wuhan YZY Biopharma Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate
PremiumCompany Announcements
Wuhan YZY Biopharma Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate
3M ago
2496
YZY Biopharma’s M701 Shows Promising Phase III Data Ahead of 2026 ASCO
PremiumCompany Announcements
YZY Biopharma’s M701 Shows Promising Phase III Data Ahead of 2026 ASCO
3M ago
2496
Wuhan YZY Biopharma Reshapes Supervisory Committee With New Employee Representative
PremiumCompany AnnouncementsWuhan YZY Biopharma Reshapes Supervisory Committee With New Employee Representative
4M ago
2496
YZY Biopharma’s Lead Cancer Bispecific M701 Wins NMPA NDA Acceptance
Premium
Company Announcements
YZY Biopharma’s Lead Cancer Bispecific M701 Wins NMPA NDA Acceptance
4M ago
2496
YZY Biopharma’s M701 Data Secured for High-Profile ASCO 2026 Presentations
Premium
Company Announcements
YZY Biopharma’s M701 Data Secured for High-Profile ASCO 2026 Presentations
4M ago
2496
Wuhan YZY Biopharma Completes Full Circulation of H Shares to Boost Market Liquidity
PremiumCompany Announcements
Wuhan YZY Biopharma Completes Full Circulation of H Shares to Boost Market Liquidity
5M ago
2496
Wuhan YZY Biopharma Swings to Net Liabilities as 2025 Revenue Falls
PremiumCompany Announcements
Wuhan YZY Biopharma Swings to Net Liabilities as 2025 Revenue Falls
5M ago
2496
Wuhan YZY Biopharma Sets March Board Meeting to Approve 2025 Final Results
PremiumCompany Announcements
Wuhan YZY Biopharma Sets March Board Meeting to Approve 2025 Final Results
5M ago
2496
Wuhan YZY Biopharma Confirms Land and Building Transfer Will Not Affect R&D or Commercial Plans
PremiumCompany Announcements
Wuhan YZY Biopharma Confirms Land and Building Transfer Will Not Affect R&D or Commercial Plans
7M ago
2496
Wuhan YZY Biopharma Wins HKEX Approval for Full H-Share Circulation of 35% Stake
PremiumCompany AnnouncementsWuhan YZY Biopharma Wins HKEX Approval for Full H-Share Circulation of 35% Stake
7M ago
2496
Wuhan YZY Biopharma Wins FDA IND Approval for Bispecific Antibody M701 in Malignant Pleural Effusion
Premium
Company Announcements
Wuhan YZY Biopharma Wins FDA IND Approval for Bispecific Antibody M701 in Malignant Pleural Effusion
7M ago
2496
Wuhan YZY Biopharma Clears CSRC Filing for H Share Full Circulation Plan
Premium
Company Announcements
Wuhan YZY Biopharma Clears CSRC Filing for H Share Full Circulation Plan
7M ago
2496
Wuhan YZY Biopharma to Transfer Wuhan Industrial Land and Building for RMB36.88 Million
PremiumCompany Announcements
Wuhan YZY Biopharma to Transfer Wuhan Industrial Land and Building for RMB36.88 Million
7M ago
2496
Wuhan YZY Biopharma Reshapes Supervisory Committee With New Employee Representative Supervisor
PremiumCompany Announcements
Wuhan YZY Biopharma Reshapes Supervisory Committee With New Employee Representative Supervisor
8M ago
2496
Wuhan YZY Biopharma Wins NMPA IND Nod for Hemlibra Biosimilar Y225 and Deepens Antibody R&D Push
PremiumCompany Announcements
Wuhan YZY Biopharma Wins NMPA IND Nod for Hemlibra Biosimilar Y225 and Deepens Antibody R&D Push
8M ago
2496
Wuhan YZY Biopharma’s M701 Shows Promising Results in Phase II Trial
PremiumCompany Announcements
Wuhan YZY Biopharma’s M701 Shows Promising Results in Phase II Trial
9M ago
2496
Wuhan YZY Biopharma Reports Promising Phase II Results for M701 in Treating Malignant Pleural Effusion
PremiumCompany AnnouncementsWuhan YZY Biopharma Reports Promising Phase II Results for M701 in Treating Malignant Pleural Effusion
10M ago
2496
Wuhan YZY Biopharma Announces Change in Supervisory Committee
Premium
Company Announcements
Wuhan YZY Biopharma Announces Change in Supervisory Committee
11M ago
2496
Wuhan YZY Biopharma Reports Interim 2025 Financial Results Amid R&D Focus
Premium
Company Announcements
Wuhan YZY Biopharma Reports Interim 2025 Financial Results Amid R&D Focus
1y ago
2496

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >